Physician profile
Amber Roffe
NPI 1831746320
$1,114.18
in general payments reported to CMS, 2019-2025
14 companies · $376 in 2025
The $376 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $161 · 2022: $202 · 2023: $86.49 · 2024: $289 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $751.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $366.17 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $327.19 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $88.68 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $88.57 | 2022-2025 | Uzedy, Austedo Xr |
| Axsome Therapeutics, INC. | $47.70 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $36.70 | 2024 | Cobenfy |
| Vanda Pharmaceuticals INC. | $26.88 | 2024 | Hetlioz, Fanapt |
| Indivior INC. | $25.35 | 2023 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.23 | 2024 | Caplyta |
| Neurocrine Biosciences, INC. | $20.66 | 2025 | |
| Lundbeck LLC | $18.00 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $17.23 | 2024 | Trintellix |
| Novo Nordisk INC | $16.16 | 2024 | |
| Lilly USA, LLC | $13.66 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Roffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.